Harpoon Therapeutics Abstract For HPN217 Accepted For Presentation At The 65th American Society Of Hematology Annual Meeting And Exposition
Portfolio Pulse from Benzinga Newsdesk
Harpoon Therapeutics, Inc. (NASDAQ:HARP) has announced that the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The event will take place from December 9-12, 2023, in San Diego.
November 02, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harpoon Therapeutics' announcement of the presentation of Phase 1 study results of HPN217 at the ASH Annual Meeting could potentially boost investor confidence in the company's ongoing research and development efforts.
The presentation of positive results from a Phase 1 study is typically seen as a positive development for a biotech company like Harpoon Therapeutics. This could potentially lead to increased investor confidence in the company's research and development capabilities, which could in turn have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100